Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341502 | 0.87 | KDM4E (0.47) | PTGS2CSF1RMAPTSOS1ALOX15 | |
| SCHEMBL3426199 | 0.86 | CSF1R (0.44) | PTGS2CSF1RMAPTSOS1ATM | |
| SCHEMBL13841942 | 0.86 | KMT2A (0.51) | PTGS2CSF1RMAPTSOS1ALOX15 | |
| SCHEMBL3429050 | 0.86 | MAP2K1 (0.47) | PTGS2MAPTCLCN2CYP1A2CYP2C19 | |
| SCHEMBL19367457 | 0.85 | PTGS2 (0.46) | PTGS2CSF1RALOX5MAPTALOX15 | |
| SCHEMBL14428417 | 0.85 | PTGS2 (0.46) | PTGS2CSF1RALOX5MAPTALOX15 | |
| SCHEMBL3426662 | 0.85 | PTGS2 (0.46) | PTGS2CSF1RALOX5MAPTALOX15 | |
| SCHEMBL3969081 | 0.82 | SRC (0.46) | PTGS2CSF1RALOX5MAPTALOX15 | |
| SCHEMBL1077964 | 0.81 | PTGS2 (0.45) | PTGS2CSF1RALOX5MAPTALOX15 | |
| SCHEMBL15129388 | 0.81 | PTGS2 (0.44) | PTGS2CSF1RALOX5MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| EP-2804855-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | Tianjin Binjiang Pharma, Inc. (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | PTGS2 1213/4885CSF1R 1571/4885ALOX5 1330/4885 |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, CDK1, MAP3K1 | PTGS2 218/4885CSF1R 1686/4885ALOX5 1062/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | PTGS2 1115/4885CSF1R 1633/4885ALOX5 1299/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | PTGS2 1276/4885CSF1R 1664/4885ALOX5 1487/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | PTGS2 1115/4885CSF1R 1633/4885ALOX5 1299/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | PTGS2 12/4885CSF1R 1311/4885ALOX5 48/4885 |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, MAPK1, BDKRB1 | PTGS2 257/4885CSF1R 1661/4885ALOX5 1098/4885 |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | PTGS2 1226/4885CSF1R 1736/4885ALOX5 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.